Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential [Seeking Alpha]
Mesoblast Limited - American Depositary Shares (MESO)
US:NASDAQ Investor Relations:
investorsmedia.mesoblast.com
Company Research
Source: Seeking Alpha
Follow Play 13min Summary Mesoblast Limited is advancing innovative cellular therapies, with Remestemcel-L for pediatric SR-aGVHD nearing FDA approval and a PDUFA date set for January 2025. Positive Phase 3 results indicate that Remestemcel-L significantly improves response rates and survival in pediatric patients. Additionally, Mesoblast's pipeline includes late-stage therapies for chronic low back pain and heart failure, both of which are showing promising results and are nearing regulatory approval. MESO appears significantly undervalued compared to its potential, with a strong cash position and strategic partnerships to support upcoming product launches. Despite regulatory and market adoption risks, MESO's upside potential justifies a “Strong Buy” rating for investors familiar with these risks. Md Babul Hosen Mesoblast Limited NASDAQ: MESO ) promising innovative cellular therapies are quickly progressing towards FDA approval. MESO's therapies can potentially t
Show less
Read more
Impact Snapshot
Event Time:
MESO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MESO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MESO alerts
High impacting Mesoblast Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MESO
News
- Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings [Yahoo! Finance]Yahoo! Finance
- Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation MeetingsGlobeNewswire
- Mesoblast Limited (NASDAQ: MESO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $24.00 price target on the stock, up previously from $15.00.MarketBeat
- Mesoblast Limited (NASDAQ: MESO) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.MarketBeat
- Ryoncil® Commercial Launch Update and Product PipelineGlobeNewswire